Analysis of a clinical pathway for the use of long-acting injectable antiretroviral therapy in adherence challenged people living with HIV
{{output}}
BackgroundLong-acting injectable cabotegravir/rilpivirine (LA-CAB/RPV) is approved for people with HIV (PWH) who have achieved virological suppression; however, evidence remains limited for individuals with adherence challenges including those with persistent ... ...
